Pfizer launches clinical trial of omicron-specific vaccine By Tom Howell Jr. - The Washington Times Shares
COVID-19 pill rollout stymied by shortages as omicron rages By Matthew Perrone - Associated Press Shares
FDA and its flimsy COVID-19 FOIA dodge falls flat with federal judge By Cheryl K. Chumley - The Washington Times Shares
Hospitalizations skyrocket in kids too young for COVID shots By Lindsey Tanner and Mike Stobbe - Associated Press Shares
U.S. urges COVID boosters starting at age 12 to fight omicron By Lauran Neergaard and Mike Stobbe - Associated Press Shares
Biden’s Christmas crisis: 2021 ends with 400K more COVID-19 deaths By Tom Howell Jr. - The Washington Times Shares
CDC panel recommends Pfizer, Moderna shots over J&J vaccine, citing rare blood-clotting side effect By Tom Howell Jr. - The Washington Times Shares
Pfizer: COVID-19 pills were 89% against hospitalization, death; fought back omicron in lab studies By Tom Howell Jr. - The Washington Times Shares
Pfizer jabs protect 70% against hospitalization from omicron By Andrew Meldrum - Associated Press Shares
FDA expands Pfizer COVID booster, opens extra dose to age 16 By Lauran Neergaard and Matthew Perrone - Associated Press Shares
Pfizer: Early lab findings show booster protects against omicron variant By Tom Howell Jr. - The Washington Times Shares
Omicron variant spreading fast, but scientists call it mild, warn not to panic By Tom Howell Jr. - The Washington Times Shares
EU regulator authorizes Pfizer’s COVID-19 vaccine for kids 5-11 By Mike Corder and Maria Cheng - Associated Press Shares
Germany faces grim COVID milestone with leadership in flux By Daniel Niemann and Frank Jordans - Associated Press Shares
